Large Cap - Spark Newswire

1 minute read

GSK/Pfizer-Backed ViiV Healthcare’s HIV Treatment At Par With Gilead’s: Study Shows

Today, 4:38 PM

ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…

GILD

1 minute read

GSK, Pfizer And Shionogi Owned ViiV Healthcare Announced 12-month Findings From The Solar Phase 3B Head-to-head Study Of Long Acting Cabenuva Regime (CAB+RPV LA) Compared Against Gilead’s Biktarvy Regime (BIC/FTC/TAF)

By Benzinga Newsdesk

Today, 4:38 PM

Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV

GSK

2 minute read

EXCLUSIVE: Benzinga’s Favorite Hedge Funds To Watch During 13F Season

By AJ Fabino

Today, 4:38 PM

It’s hedge fund season. Hedge funds with more than $100 million in assets are required to file a Form 13F with the U.S. Securities and Exchange Commission (SEC) within 45 days of the end of each calendar quarter. The last deadline was Feb. 14 for the fiscal quarter ending Dec. 31.

AAPL

2 minute read

What’s More Expensive: Buying A House, Or Building One?

By AJ Fabino

Today, 4:38 PM

The housing market has been top-of-mind for new and would-be homeowners for months, as the Federal Reserve’s aggressive rate hike campaign has kept mortgage rates at highs last seen since 2007. And it’s not just expensive borrowing costs keeping people in their apartments.

DHI

1 minute read

Astrazeneca’s Tablet Formulation Of Calquence (Acalabrutinib) Has Been Approved In The European Union (Eu) For Adult Patients With Chronic Lymphocytic Leukemia.

By Benzinga Newsdesk

Today, 4:38 PM

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the ELEVATE-PLUS trials published in the American Society of

AZN

1 minute read

US Supreme Court Refuses To Reject $302M Judgment Against Johnson & Johnson Over Pelvic Mesh Marketing

By Vandana Singh

Today, 4:38 PM

The U.S. Supreme Court refused to hear Johnson & Johnson's (NYSE: JNJ) regarding a $302 million judgment in a lawsuit brought by California, accusing the company of concealing the risks of its pelvic mesh products.

JNJ

1 minute read

Merck’s COVID-19 Treatment Fails To Prevent Infection In Household Exposure

By Vandana Singh

Today, 4:38 PM

Merck & Co Inc (NYSE:MRK) Lagevrio (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household…

MRK